Showing 2 posts of 2 posts found.


Gilead’s selonsertib crashes at Phase 3 in NASH

April 26, 2019
Medical Communications, Research and Development, Sales and Marketing Gilead, nash, pharma, selonsertib

Gilead has broken the news that its apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib failed to meet its primary endpoint …


Gilead shares drop 4% after failure of NASH drug to meet primary endpoint

February 12, 2019
Manufacturing and Production Gilead, Shares, fatty liver disease, nash, selonsertib

Gilead’s treatment for the progressive fatty liver disease, NASH, has failed to meet its primary goal in a phase 3 …

Latest content